← back to search

Uday Popat

The University of Texas MD Anderson Cancer Center · US
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, and Acute Lymphoblastic Leukemia research.
h-index
68
citations
17,084
works
996
NIH funding
primary concept
email

Recent publications

An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed Therapy
Transplantation and Cellular Therapy 2025cited by 6position: middledoi
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT
Bone Marrow Transplantation 2024cited by 58position: middledoi
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease
Blood Advances 2024cited by 7position: middledoi
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes
Transplantation and Cellular Therapy 2021cited by 31position: middledoi
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD
Bone Marrow Transplantation 2021cited by 23position: middledoi
RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML
Blood Advances 2020cited by 152position: middledoi
Survival following allogeneic transplant in patients with myelofibrosis
Blood Advances 2020cited by 96position: middledoi
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes
Blood Advances 2020cited by 72position: middledoi
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report
Blood Advances 2020cited by 34position: middledoi
Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i>− MPN with de novo AML and with AML following MDS
Blood Advances 2020cited by 19position: middledoi
Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial
The Lancet Haematology 2019cited by 102position: middledoi
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
Biology of Blood and Marrow Transplantation 2019cited by 35position: middledoi
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
Leukemia Research 2018cited by 68position: middledoi
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
Blood Advances 2018cited by 42position: middledoi
Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion
Blood 2018cited by 30position: middledoi
Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia
Biology of Blood and Marrow Transplantation 2017cited by 62position: middledoi
Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes
Biology of Blood and Marrow Transplantation 2017cited by 22position: middledoi
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis
Biology of Blood and Marrow Transplantation 2016cited by 98position: middledoi
Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial
Blood 2016cited by 94position: middledoi
The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes
Haematologica 2016cited by 75position: middledoi
Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations
Blood 2016cited by 4position: middledoi
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
Leukemia 2015cited by 269position: middledoi
Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation
Biology of Blood and Marrow Transplantation 2015cited by 213position: middledoi
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
Biology of Blood and Marrow Transplantation 2015cited by 142position: middledoi
Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation
Biology of Blood and Marrow Transplantation 2015cited by 76position: middledoi
Better allele-level matching improves transplant-related mortality after double cord blood transplantation
Haematologica 2015cited by 34position: middledoi
Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis
Journal of Clinical Oncology 2014cited by 184position: middledoi
High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS)
JAMA Neurology 2014cited by 178position: middledoi
Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections
Journal of Antimicrobial Chemotherapy 2013cited by 153position: middledoi
Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
Biology of Blood and Marrow Transplantation 2013cited by 144position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Vikas Gupta · University Health Network4 papers (2012–2016)Richard E. Champlin · The University of Texas MD Anderson Cancer Center4 papers (2013–2021)Marcelo C. Pasquini · Medical College of Wisconsin3 papers (2012–2020)Görgün Akpek · Rush University Medical Center3 papers (2012–2016)Nicolaus Kröger · Universität Ulm3 papers (2015–2025) · 3 papers (2015–2021)Chitra Hosing · The University of Texas MD Anderson Cancer Center3 papers (2013–2021)Robert J. Soiffer · Harvard University2 papers (2024–2025)Partow Kebriaei · Scripps MD Anderson Cancer Center2 papers (2015–2021)Richard T. Maziarz · Medical College of Wisconsin2 papers (2012–2016)Betül Oran · The University of Texas MD Anderson Cancer Center2 papers (2015–2021)Bipin N. Savani · Medical College of Wisconsin2 papers (2015–2024)Stefan O. Ciurea · University of California, Irvine2 papers (2015–2021)Kai Cao · Beijing Tongren Hospital2 papers (2015–2015)Sumithira Vasu · The Ohio State University Wexner Medical Center2 papers (2015–2025)Andrea Bacigalupo · Advanced Radiation Therapy (United States)2 papers (2015–2024) · 2 papers (2015–2015)Olle Ringdén · Karolinska University Hospital2 papers (2012–2016)Steven M. Devine · Memorial Sloan Kettering Cancer Center2 papers (2014–2016)Marcelo Fernández-Viña · Palo Alto University2 papers (2015–2015)